<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vivani Medical Inc. — News on 6ix</title>
<link>https://6ix.com/company/vivani-medical-inc</link>
<description>Latest news and press releases for Vivani Medical Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vivani-medical-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d12378dffbe2df11f945.webp</url>
<title>Vivani Medical Inc.</title>
<link>https://6ix.com/company/vivani-medical-inc</link>
</image>
<item>
<title>Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature,</description>
</item>
<item>
<title>Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-subsidiary-cortigent-presents-promising-123000540</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-subsidiary-cortigent-presents-promising-123000540</guid>
<pubDate>Thu, 29 Jan 2026 12:30:00 GMT</pubDate>
<description>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical</description>
</item>
<item>
<title>Vivani Medical, Inc. Announces Closing of Common Stock Offering</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-inc-announces-closing-210500912</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-inc-announces-closing-210500912</guid>
<pubDate>Tue, 27 Jan 2026 21:05:00 GMT</pubDate>
<description>ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per s</description>
</item>
<item>
<title>Vivani Medical, Inc. Announces Pricing of Common Stock Offering</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-inc-announces-pricing-043600842</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-inc-announces-pricing-043600842</guid>
<pubDate>Mon, 26 Jan 2026 04:36:00 GMT</pubDate>
<description>ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg W</description>
</item>
<item>
<title>Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-subsidiary-cortigent-present-orion-120000709</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-subsidiary-cortigent-present-orion-120000709</guid>
<pubDate>Thu, 22 Jan 2026 12:00:00 GMT</pubDate>
<description>Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company’s new Orion cortical stimulation system for visual perception, designed to treat most common forms of blindness, successfully completed a six-year Early Feasibility Study Cortigent is also developing a new medical device aimed at improving the recovery of arm and hand motion in patients suffering from paralysis due to stroke ALAMEDA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Viv</description>
</item>
<item>
<title>Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-business-reports-124500829</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-business-reports-124500829</guid>
<pubDate>Thu, 13 Nov 2025 12:45:00 GMT</pubDate>
<description>Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback 3Q 2025 private placement, together with October financings, generated approximately $25.7M in cash and cash commitments to support accelerated development of NPM-139 while securing financial position into 2027 ALAMEDA, Calif., No</description>
</item>
<item>
<title>Vivani Medical to Present at the ThinkEquity Conference on October 30, 2025</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-thinkequity-conference-123000447</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-thinkequity-conference-123000447</guid>
<pubDate>Wed, 22 Oct 2025 12:30:00 GMT</pubDate>
<description>ALAMEDA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that Chief Executive Officer Adam Mendelsohn, Ph.D., will provide a Company Presentation at the ThinkEquity Conference on October 30, 2025 in New York. Event details are as follows:Presentation Date: Thursday, October 30, 2025Presentation Time: 1:30 p.m. Eastern TimeLoc</description>
</item>
<item>
<title>Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-withdraws-record-date-123000895</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-withdraws-record-date-123000895</guid>
<pubDate>Fri, 03 Oct 2025 12:30:00 GMT</pubDate>
<description>The Company expects to reestablish and announce a new record date as soon as possibleALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that the Company will temporarily withdraw the previously announced record date for the planned spin-off of Cortigent, Inc. (“Cortigent”), its wholly-owned subsidiary developing brain i</description>
</item>
<item>
<title>Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-emerging-growth-131500667</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-emerging-growth-131500667</guid>
<pubDate>Wed, 24 Sep 2025 13:15:00 GMT</pubDate>
<description>ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will present at the Emerging Growth Conference 86 on September 25, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and</description>
</item>
<item>
<title>Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-announces-record-date-123000612</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-announces-record-date-123000612</guid>
<pubDate>Wed, 17 Sep 2025 12:30:00 GMT</pubDate>
<description>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients w</description>
</item>
<item>
<title>Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-clinical-development-123000638</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-clinical-development-123000638</guid>
<pubDate>Thu, 04 Sep 2025 12:30:00 GMT</pubDate>
<description>NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM-139 to occur in parallel with Phase 1 study ALAMEDA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing novel, ultra long-acting dru</description>
</item>
<item>
<title>Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-ceo-adam-mendelsohn-123000106</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-ceo-adam-mendelsohn-123000106</guid>
<pubDate>Wed, 20 Aug 2025 12:30:00 GMT</pubDate>
<description>ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn’s presentation are a</description>
</item>
<item>
<title>Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-business-including-202000972</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-business-including-202000972</guid>
<pubDate>Wed, 13 Aug 2025 20:20:00 GMT</pubDate>
<description>Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body function</description>
</item>
<item>
<title>Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-announces-rapid-advancement-121000499</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-announces-rapid-advancement-121000499</guid>
<pubDate>Tue, 05 Aug 2025 12:10:00 GMT</pubDate>
<description>LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study’s primary objectives New NPM-139 (semaglutide implant) preclinical feasibility data showed approximately 20% weight loss maintained longer than 6 months with a single implant, continuing to support the potential for annual dosing Based on these data, Vivani prioritizes the advancement of N</description>
</item>
<item>
<title>Vivani Medical Appoints Anthony Baldor as Chief Financial Officer</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-appoints-anthony-baldor-120000154</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-appoints-anthony-baldor-120000154</guid>
<pubDate>Wed, 11 Jun 2025 12:00:00 GMT</pubDate>
<description>ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus on her board appointments and personal projects after a distinguished career and significant contributions to the Company. Baldo</description>
</item>
<item>
<title>Vivani Medical to Present at the 2025 BIO International Convention</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-2025-bio-123000429</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-2025-bio-123000429</guid>
<pubDate>Tue, 10 Jun 2025 12:30:00 GMT</pubDate>
<description>ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the 2025 BIO International Convention, taking place from June 16-19, 2025 in Boston, Massachusetts. Details around Dr. Mendelsohn’s presentation are as follows: Date:Wedn</description>
</item>
<item>
<title>Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-announces-filing-form-123000989</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-announces-filing-form-123000989</guid>
<pubDate>Thu, 29 May 2025 12:30:00 GMT</pubDate>
<description>Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered paralysis due to stroke Spin-off will allow Vivani to focus on its continued de</description>
</item>
<item>
<title>Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-business-including-203000477</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-provides-business-including-203000477</guid>
<pubDate>Tue, 13 May 2025 20:30:00 GMT</pubDate>
<description>All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 Announced new $3M equity financing together with the previously reported $8.25M equity financing secures financial position into mid-2026 Promising pre-clinical data released for NPM-139 (semaglutide implant) for chronic weight management in obese and overweight p</description>
</item>
<item>
<title>Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-american-association-123000322</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-present-american-association-123000322</guid>
<pubDate>Wed, 07 May 2025 12:30:00 GMT</pubDate>
<description>ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists’ (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025. Presentatio</description>
</item>
<item>
<title>Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company</title>
<link>https://6ix.com/company/vivani-medical-inc/news/vivani-medical-participate-virtual-fireside-123000433</link>
<guid isPermaLink="true">https://6ix.com/company/vivani-medical-inc/news/vivani-medical-participate-virtual-fireside-123000433</guid>
<pubDate>Wed, 16 Apr 2025 12:30:00 GMT</pubDate>
<description>Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company’s LIBERATE-1 clinical trial from which topline data is anticipated in mid-year 2025 ALAMEDA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug imp</description>
</item>
</channel>
</rss>